$40M ‘longevity fund’ that’s looking to ‘make death optional’

Key Points:

• Immortal Dragons, a Singapore-based longevity fund founded by CEO Boyang Wang, focuses on high-risk, high-reward investments aimed at extending human life and combating age-related diseases through innovative technologies like 3D biofabrication and gene therapies.
• The fund supports projects such as Frontier Bio, which develops organ printing to reduce transplant wait times, and research into creating nonsentient mammals for ethical medical testing, highlighting novel approaches to medical challenges.
• Immortal Dragons also advocates for progressive policies, exemplified by their role in supporting New Hampshire’s “Right to Try” law, which allows terminally ill patients access to experimental treatments, fostering biomedical research and patient autonomy.
• Neuroscience research funded by the organization, including work by Stanford post-doctoral student Andy Tsai, aims to understand genetic factors behind longevity and neurodegenerative diseases, with the goal of extending healthy lifespan and reducing age-related decline.
• While longevity research faces criticism as a billionaire-driven endeavor amid widespread social inequalities, proponents argue it offers broad societal benefits by potentially reducing healthcare burdens and improving quality of life for aging populations.